Inhibition of plasminogen activation by apo(a): Role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a)

Journal of Lipid Research

Volumn 55, Issue 4, 2014, Pages 625-634

  Romagnuolo, Rocco ^a   Marcovina, Santica M ^b   Boffa, Michael B ^a   Koschinsky, Marlys L ^a  

^a UNIVERSITY OF WINDSOR   (Canada)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Apolipoprotein(a); Atherosclerosis; Carboxypeptidase B; Fibrinolysis; Lipoprotein(a); Thrombin activatable fibrinolysis inhibitor; Tissue type plasminogen activator

Indexed keywords

APOLIPOPROTEIN A; CARBOXYPEPTIDASE; LYSINE; PLASMINOGEN; PLASMINOGEN ACTIVATOR; PROTEIN BINDING;

ANIMAL CELL; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CELL DENSITY; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MACROPHAGE; MOLECULAR DYNAMICS; MONOCYTE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION; RAT; CELL CULTURE; CHEMISTRY; METABOLISM; MONONUCLEAR CELL; PHYSIOLOGY; UMBILICAL VEIN ENDOTHELIAL CELL;

APOLIPOPROTEINS A; CELLS, CULTURED; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LEUKOCYTES, MONONUCLEAR; LYSINE; MACROPHAGES; PLASMINOGEN; PLASMINOGEN ACTIVATORS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS;

EID: 84897405191     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M036566     Document Type: Article

References (67)

1. Berg, K. 1963. A new serum type system in man-the LP system. Acta Pathol. Microbiol. Scand. 59 : 369-382.
2. Dubé, J. B., M. B. Boffa, R. A. Hegele, and M. L. Koschinsky. 2012. Lipoprotein(a): more interesting than ever after 50 years. Curr. Opin. Lipidol. 23 : 133-140.
3. Albers, J. J., H. Kennedy, and S. M. Marcovina. 1996. Evidence that Lp(a) contains one molecule of apo(a) and one molecule of apoB: evaluation of amino acid analysis data. J. Lipid Res. 37 : 192-196.
4. Boerwinkle, E., C. C. Leffert, J. Lin, C. Lackner, G. Chiesa, and H.H. Hobbs. 1992. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J. Clin. Invest. 90 : 52-60.
5. Koschinsky, M. L. 2006. Novel insights into Lp(a) physiology and pathogenicity: more questions than answers? Cardiovasc. Hematol. Disord. Drug Targets. 6 : 267-278.
6. Anuurad, E., M. B. Boffa, M. L. Koschinsky, and L. Berglund. 2006. Lipoprotein(a): a unique risk factor for cardiovascular disease. Clin. Lab. Med. 26 : 751-772.
7. Nordestgaard, B. G., M. J. Chapman, K. Ray, J. Borén, F. Andreotti, G. F. Watts, H. Ginsberg, P. Amarenco, A. Catapano, O. S. Descamps, et al .; European Atherosclerosis Society Consensus Panel. 2010. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J. 31 : 2844-2853.
8. Ariyo, A. A., C. Thach, and R. Tracy ; Cardiovascular Health Study Investigators. 2003. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N. Engl. J. Med. 349 : 2108-2115.
9. Dieplinger, B., A. Lingenhel, N. Baumgartner, W. Poelz, H. Dieplinger, M. Haltmayer, F. Kronenberg, and T. Mueller. 2007. Increased serum lipoprotein(a) concentrations and low molecular weight phenotypes of apolipoprotein(a) are associated with symptomatic peripheral arterial disease. Clin. Chem. 53 : 1298-1305.
10. Bennet, A., E. Di Angelantonio, S. Erqou, G. Eiriksdottir, G. Sigurdsson, M. Woodward, A. Rumley, G. D. Lowe, J. Danesh, and V. Gudnason. 2008. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch. Intern. Med. 168 : 598-608.
11. Kamstrup, P. R. 2010. Lipoprotein(a) and ischemic heart disease-a causal association? A review. Atherosclerosis. 211 : 15-23.
12. Sofi, F., R. Marcucci, R. Abbate, G. F. Gensini, and D. Prisco. 2007. Lipoprotein (a) and venous thromboembolism in adults: a metaanalysis. Am. J. Med. 120 : 728-733.
13. McLean, J. W., J. E. Tomlinson, W. J. Kuang, D. L. Eaton, E. Y. Chen, G. M. Fless, A. M. Scanu, and R. M. Lawn. 1987. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 330 : 132-137.
14. van der Hoek, Y. Y., M. E. Wittekoek, U. Beisiegel, J. J. Kastelein, and M. L. Koschinsky. 1993. The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms. Hum. Mol. Genet. 2 : 361-366.
15. Lackner, C., J. C. Cohen, and H. H. Hobbs. 1993. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum. Mol. Genet. 2 : 933-940.
16. Marcovina, S. M., J. J. Albers, E. Wijsman, Z. Zhang, N. H. Chapman, and H. Kennedy. 1996. Differences in Lp(a) concentrations and apo(a) polymorphs between black and white Americans. J. Lipid Res. 37 : 2569-2585.
17. Gabel, B. R., and M. L. Koschinsky. 1995. Analysis of the proteolytic activity of a recombinant form of apolipoprotein(a). Biochemistry. 34 : 15777-15784.
18. Ernst, A., M. Helmhold, C. Brunner, A. Pethö-Schramm, V. W. Armstrong, and H. J. Müller. 1995. Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a). J. Biol. Chem. 270 : 6227-6234.
19. Gabel, B. R., and M. L. Koschinsky. 1998. Sequences within apolipoprotein(a) kringle IV types 6-8 bind directly to low-density lipoprotein and mediate noncovalent association of apolipoprotein(a) with apolipoprotein B-100. Biochemistry. 37 : 7892-7898.
20. Becker, L., P. M. Cook, T. G. Wright, and M. L. Koschinsky. 2004. Quantitative evaluation of the contribution of weak lysine-binding sites present within apolipoprotein(a) kringle IV types 6-8 to lipoprotein(a) assembly. J. Biol. Chem. 279 : 2679-2688.
21. Koschinsky, M. L., G. P. Côté, B. Gabel, and Y. Y. van der Hoek. 1993. Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100. J. Biol. Chem. 268 : 19819-19825.
22. Becker, L., P. M. Cook, and M. L. Koschinsky. 2004. Identification of sequences in apolipoprotein(a) that maintain its closed conformation: a novel role for apo(a) isoform size in determining the efficiency of covalent Lp(a) formation. Biochemistry. 43 : 9978-9988.
23. Hoover-Plow, J. L., L. A. Miles, G. M. Fless, A. M. Scanu, and E. F. Plow. 1993. Comparison of the lysine binding functions of lipoprotein(a) and plasminogen. Biochemistry. 32 : 13681-13687.
24. Miles, L. A., S. B. Hawley, N. Baik, N. M. Andronicos, F. J. Castellino, and R. J. Parmer. 2005. Plasminogen receptors: the sine qua non of cell surface plasminogen activation. Front. Biosci. 10 : 1754-1762.
25. Hoylaerts, M., D. C. Rijken, H. R. Lijnen, and D. Collen. 1982. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J. Biol. Chem. 257 : 2912-2919.
26. Das, R., E. Pluskota, and E. F. Plow. 2010. Plasminogen and its receptors as regulators of cardiovascular inflammatory responses. Trends Cardiovasc. Med. 20 : 120-124.
27. Busuttil, S. J., V. A. Ploplis, F. J. Castellino, L. Tang, J. W. Eaton, and E. F. Plow. 2004. A central role for plasminogen in the inflammatory response to biomaterials. J. Thromb. Haemost. 2 : 1798-1805.
28. Plow, E. F., T. Herren, A. Redlitz, L. A. Miles, and J. L. Hoover-Plow. 1995. The cell biology of the plasminogen system. FASEB J. 9 : 939-945.
29. Mignatti, P., and D. B. Rifkin. 1996. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein. 49 : 117-137.
30. Hajjar, K. A., P. C. Harpel, E. A. Jaffe, and R. L. Nachman. 1987. Binding of plasminogen to cultured human endothelial cells. J. Biol. Chem. 261 : 11656-11662.
31. Plow, E. F., D. E. Freaney, J. Plescia, and L. A. Miles. 1986. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J. Cell Biol. 103 : 2411-2420.
32. Gong, Y., S. O. Kim, J. Felez, D. K. Grella, F. J. Castellino, and L. A. Miles. 2001. Conversion of Glu-plasminogen to Lys-plasminogen is necessary for optimal stimulation of plasminogen activation on the endothelial cell surface. J. Biol. Chem. 276 : 19078-19083.
33. Hancock, M. A., M. B. Boffa, S. M. Marcovina, M. E. Nesheim, and M. L. Koschinsky. 2003. Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J. Biol. Chem. 278 : 23260-23269.
34. Feric, N. T., M. B. Boffa, S. M. Johnston, and M. L. Koschinsky. 2008. Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation. J. Thromb. Haemost. 6 : 2113-2120.
35. O'Neil, C. H., M. B. Boffa, M. A. Hancock, J. G. Pickering, and M. L. Koschinsky. 2004. Stimulation of vascular smooth muscle cell proliferation and migration by apolipoprotein(a) is dependent on inhibition of transforming growth factor-beta activation and on the presence of kringle IV type 9. J. Biol. Chem. 279 : 55187-55195.
36. Kojima, S., P. C. Harpel, and D. B. Rifkin. 1991. Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J. Cell Biol. 113 : 1439-1445.
37. Grainger, D. J., H. L. Kirschenlohr, J. C. Metcalfe, P. L. Weissberg, D. P. Wade, and R. M. Lawn. 1993. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science. 260 : 1655-1658.
38. Godier, A., and B. J. Hunt. 2013. Plasminogen receptors and their role in the pathogenesis of inflammatory, autoimmune and malignant disease. J. Thromb. Haemost. 11 : 26-34.
39. Félez, J., L. A. Miles, P. Fábregas, M. Jardí, E. F. Plow, and H. R. Lijnen. 1996. Characterization of cellular binding sites and interactive regions within reactants required for enhancement of plasminogen activation by tPA on the surface of leukocytic cells. Thromb. Haemost. 76 : 577-584.
40. Miles, L. A., N. M. Andronicos, N. Baik, and R. J. Parmer. 2006. Cellsurface actin binds plasminogen and modulates neurotransmitter release from catecholaminergic cells. J. Neurosci. 26 : 13017-13024.
41. Fogg, D. K., D. E. Bridges, K. K. Cheung, G. Kassam, N. R. Filipenko, K. S. Choi, S. L. Fitzpatrick, M. Nesheim, and D. M. Waisman. 2002. The p11 subunit of annexin II heterotetramer is regulated by basic carboxypeptidase. Biochemistry. 41 : 4953-4961.
42. Okumura, N., T. Koh, Y. Hasebe, T. Seki, and T. Ariga. 2009. A novel function of thrombin-activatable fibrinolysis inhibitor during rat liver regeneration and in growth-promoted hepatocytes in primary culture. J. Biol. Chem. 284 : 16553-16561.
43. Miles, L. A., G. M. Fless, E. G. Levin, A. M. Scanu, and E. F. Plow. 1989. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature. 339 : 301-303.
44. Hajjar, K. A., D. Gavish, J. L. Breslow, and R. L. Nachman. 1989. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 339 : 303-305.
45. Koschinsky, M. L., S. M. Marcovina, L. F. May, and B. R. Gabel. 1997. Analysis of the mechanism of lipoprotein(a) assembly. Clin. Genet. 52 : 338-346.
46. Sangrar, W., B. R. Gabel, M. B. Boffa, J. B. Walker, M. A. Hancock, S. M. Marcovina, A. J. Horrevoets, M. E. Nesheim, and M. L. Koschinsky. 1997. The solution phase interaction between apolipoprotein( a) and plasminogen inhibits the binding of plasminogen to a plasmin-modified fibrinogen surface. Biochemistry. 36 : 10353-10363.
47. Koschinsky, M. L., J. E. Tomlinson, T. F. Zioncheck, K. Schwartz, D. L. Eaton, and R. M. Lawn. 1991. Apolipoprotein(a): expression and characterization of a recombinant form of the protein in mammalian cells. Biochemistry. 30 : 5044-5051.
48. Keesler, G. A., B. R. Gabel, C. M. Devlin, M. L. Koschinsky, and I. Tabas. 1996. The binding activity of the macrophage lipoprotein(a)/ apolipoprotein(a) receptor is induced by cholesterol via a posttranslational mechanism and recognizes distinct kringle domains on apolipoprotein(a). J. Biol. Chem. 271 : 32096-32104.
49. Castellino, F. J., and J. R. Powell. 1981. Human plasminogen. Methods Enzymol. 80 : 365-378.
50. Perez, A., J. L. Thuillard, C. L. Bentzen, and E. J. Niesor. 2003. Expression of nuclear receptors and apo E secretion during the differentiation of monocytic THP-1 cells into macrophages. Cell Biol. Toxicol. 19 : 95-105.
51. Levin, E. G. 1983. Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzymeinhibitor complex. Proc. Natl. Acad. Sci. USA. 80 : 6804-6808.
52. Bernik, M. B., and H. C. Kwaan. 1969. Plasminogen activator activity in cultures from human tissues. An immunological and histochemical study. J. Clin. Invest. 48 : 1740-1753.
53. Duffy, M. J. 1990. Plasminogen activators and cancer. Blood Coagul. Fibrinolysis. 1 : 681-687.
54. Gao, S. W., J. Morser, K. McLean, and M. A. Shuman. 1990. Differential effect of platelets on plasminogen activation by tissue plasminogen activator, urokinase, and streptokinase. Thromb. Res. 58 : 421-433.
55. Feléz, J., C. J. Chanquia, E. G. Levin, L. A. Miles, and E. F. Plow .1991. Binding of tissue plasminogen activator to human monocytes and monocytoid cells. Blood. 78 : 2318-2327.
56. Nesheim, M., J. Walker, W. Wang, M. Boffa, A. Horrevoets, and L. Bajzar. 2001. Modulation of fibrin cofactor activity in plasminogen activation. Ann. N. Y. Acad. Sci. 936 : 247-260.
57. Plow, E. F., L. Doeuvre, and R. Das. 2012. So many plasminogen receptors: why? J. Biomed. Biotechnol. 2012 : 141806.
58. Ezratty, A., D. I. Simon, and J. Loscalzo. 1993. Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation. Biochemistry. 32 : 4628-4633.
59. Falcó, C., A. Estellés, J. Dalmau, F. España, and J. Aznar. 1998. Influence of lipoprotein (a) levels and isoforms on fibrinolytic activity-study in families with high lipoprotein (a) levels. Thromb. Haemost. 79 : 818-823.
60. Anglés-Cano, E., A. de la Peña Díaz, and S. Loyau. 2001. Inhibition of fibrinolysis by lipoprotein(a). Ann. N. Y. Acad. Sci. 936 : 261-275.
61. Kang, C., V. Durlach, T. Soulat, C. Fournier, and E. Anglés-Cano. 1997. Lipoprotein(a) isoforms display differences in affinity for plasminogen-like binding to human mononuclear cells. Arterioscler. Thromb. Vasc. Biol. 17 : 2036-2043.
62. Collen, D., and M. Verstraete. 1975. Molecular biology of human plasminogen. II. Metabolism in physiological and some pathological conditions in man. Thromb. Diath. Haemorrh. 34 : 403-408
63. Tsimikas, S., and J. L. Hall. 2012. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J. Am. Coll. Cardiol. 60 : 716-721.
64. Baldo, G., S. Giunco, D. Kontothanassis, M. R. Baiocchi, A. Valerio, and M. Frego. 2007. Different apoprotein(a) isoform proportions in serum and carotid plaque. Atherosclerosis. 193 : 177-185.
65. Koschinsky, M. L., and S. M. Marcovina. 2004. Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. Curr. Opin. Lipidol. 15 : 167-174.
66. Tomlinson, J. E., J. W. McLean, and R. M. Lawn. 1989. Rhesus monkey apolipoprotein(a). Sequence, evolution, and sites of synthesis. J. Biol. Chem. 264 : 5957-5965.
67. Belczewski, A. R., J. Ho, F. B. Taylor, Jr ., M. B. Boffa, Z. Jia, and M. L. Koschinsky. 2005. Baboon lipoprotein(a) binds very weakly to lysineagarose and fibrin despite the presence of a strong lysine-binding site in apolipoprotein(a) kringle IV type 10. Biochemistry. 44 : 555-564.